Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity. Working at Rhythm means that you are part of a team that’s passionate about transforming the lives of people living with rare genetic disorders of obesity. We recognize the courage it takes for patients and their caregivers to begin their journey of advocacy to find the answers they need. Their courage inspires us to challenge convention, ask bold questions and seek answers for them. Every day, we strive for excellence through our willingness to adapt, learn, and our tenacity to overcome barriers, together.
Rhythm Pharmaceuticals is focused on making a positive impact on patients living with rare genetic diseases of obesity (RGDO). The Territory Manager (TA) will play an integral role supporting the transformation of the care of people living with Bardet-Biedl syndrome (BBS) and Alstrom syndrome (AS) by providing disease education to a targeted physician community.
The Territory Managers will work closely with cross-functional partners to support education around clinical diagnosis in preparation for IMCIVREE’s future launch in BBS and AS and the successful execution of branded education upon product approval. This position will report to the East or West Zone Field Sales Director.
Summary of Key Responsibilities
This role will be field based.
This role will involve future travel, post availability of COVID-19 vaccine and pandemic travel guidelines.
More about Rhythm
Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity. The company is targeting the melanocortin-4 receptor (MC4R) pathway that is impaired due to genetic variants. This is a key biological pathway that regulates weight and hunger. A central element of Rhythm’s mission is to improve the understanding of these disorders and develop management strategies for patients who have no treatment options available to them. Rhythm was founded in 2008 and is based in Boston, MA. The company’s clinical development program is currently focused on several rare genetic disorders of obesity, all driven by genetic variants in the MC4R pathway. For healthcare professionals, please visit www.UNcommonObesity.com for more information. For those who may be affected or would like to learn more, visit www.LEADforRareObesity.com for more information.